Ignite Creation Date:
2025-12-24 @ 5:25 PM
Ignite Modification Date:
2026-02-22 @ 6:45 PM
Study NCT ID:
NCT03695250
Status:
TERMINATED
Last Update Posted:
2023-08-22
First Post:
2018-10-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
Sponsor:
Edward Kim
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Hepatocellular Carcinoma | View |
| None | Stage III Hepatocellular Carcinoma AJCC v8 | View |
| None | Stage IIIA Hepatocellular Carcinoma AJCC v8 | View |
| None | Stage IIIB Hepatocellular Carcinoma AJCC v8 | View |
| None | Stage IV Hepatocellular Carcinoma AJCC v8 | View |
| None | Stage IVA Hepatocellular Carcinoma AJCC v8 | View |
| None | Stage IVB Hepatocellular Carcinoma AJCC v8 | View |
| None | Unresectable Hepatocellular Carcinoma | View |
Keywords: